Roy L. Hawke

1.7k citations

33 papers · 1.4k indexed · h-index 18

Pharmacology top 0.2%
Pulmonary and Respiratory Medicine top 10%
Molecular Biology
Oncology top 10%
Pharmacology top 5%

Co-authors: Edward L. LeCluyse Celeste Lindley Stephanie Faucette Stacy S. Shord Michael Fried Zhiming Wen Bingfang Yan Sarah J. Schrieber
Topics: Drug-Induced Hepatotoxicity and Protection (13 papers)Pharmacogenetics and Drug Metabolism (11 papers)Silymarin and Mushroom Poisoning (9 papers)
Cited by: Pharmacology Hepatology
Journals: Journal of Clinical Oncology Hepatology Journal of Lipid Research
Partner nations: United States Netherlands United Kingdom

In The Last Decade

Roy L. Hawke

33 papers receiving 1.4k citations

Peers

Countries citing papers authored by Roy L. Hawke

Since Specialization

Citations

This map shows the geographic impact of Roy L. Hawke's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Roy L. Hawke with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Roy L. Hawke more than expected).

Fields of papers citing papers by Roy L. Hawke

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Roy L. Hawke. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Roy L. Hawke. The network helps show where Roy L. Hawke may publish in the future.

Co-authorship network of co-authors of Roy L. Hawke

This figure shows the co-authorship network connecting the top 25 collaborators of Roy L. Hawke. A scholar is included among the top collaborators of Roy L. Hawke based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Roy L. Hawke. Roy L. Hawke is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Interaction of Silymarin Flavonolignans with Organic Anion-Transporting Polypeptides 2013 ·Drug Metabolism and Disposition ·Kathleen Köck,Ying Xie,Roy L. Hawke,Nicholas H. Oberlies,Kim L. R. Brouwer	45
2	The Influence of Sex, Ethnicity, and CYP2B6 Genotype on Bupropion Metabolism as an Index of Hepatic CYP2B6 Activity in Humans 2012 ·Drug Metabolism and Disposition ·Katarina Ilić,Roy L. Hawke,Ranjit K. Thirumaran,Erin G. Schuetz,J. Heyward Hull,Angela D. M. Kashuba,Paul W. Stewart,Celeste Lindley,Mei-Ling Chen	21
3	Limited Sampling Estimates of Epigallocatechin Gallate Exposures in Cirrhotic and Noncirrhotic Patients With Hepatitis C After Single Oral Doses of Green Tea Extract 2012 ·Clinical Therapeutics ·Dina Halegoua‐De Marzio,Walter K. Kraft,Constantine Daskalakis,(unknown),Roy L. Hawke,Victor J. Navarro	17
4	Differences in the Disposition of Silymarin between Patients with Nonalcoholic Fatty Liver Disease and Chronic Hepatitis C 2011 ·Drug Metabolism and Disposition ·Sarah J. Schrieber,Roy L. Hawke,Zhiming Wen,Philip C. Smith,K. Rajender Reddy,Abdus S. Wahed,Steven H. Belle,Nezam H. Afdhal,Victor J. Navarro,Catherine M. Meyers,Edward Doo,Michael Fried	47
5	Phase II trial of saracatinib in patients (pts) with ER/PR-negative metastatic breast cancer (MBC). 2010 ·Journal of Clinical Oncology ·(unknown),J. A. Sparano,James F. Caravelli,Swati Patil,A. Abbruzzi,Roy L. Hawke,J. Bromberg,(unknown),Larry Norton,C. Hudis	4
6	Silymarin Ascending Multiple Oral Dosing Phase I Study in Noncirrhotic Patients With Chronic Hepatitis C 2009 ·The Journal of Clinical Pharmacology ·Roy L. Hawke,Sarah J. Schrieber,(unknown),Zhiming Wen,Philip C. Smith,K. Rajender Reddy,Abdus S. Wahed,Steven H. Belle,Nezam H. Afdhal,Victor J. Navarro,(unknown),Qiying Liu,Edward Doo,Michael Fried,(unknown)	114
7	Hepatic Metabolism and Biliary Excretion of Silymarin Flavonolignans in Isolated Perfused Rat Livers: Role of Multidrug Resistance-Associated Protein 2 (Abcc2) 2008 ·Drug Metabolism and Disposition ·Sónia Miranda,Jin Kyung Lee,Kim L. R. Brouwer,Zhiming Wen,Philip C. Smith,Roy L. Hawke	42
8	The Pharmacokinetics of Silymarin Is Altered in Patients with Hepatitis C Virus and Nonalcoholic Fatty Liver Disease and Correlates with Plasma Caspase-3/7 Activity 2008 ·Drug Metabolism and Disposition ·Sarah J. Schrieber,Zhiming Wen,Manoli Vourvahis,Philip C. Smith,Michael Fried,Angela D. M. Kashuba,Roy L. Hawke	68
9	The Influence of CYP3A5 Genotype on Dexamethasone Induction of CYP3A Activity in African Americans 2008 ·Drug Metabolism and Disposition ·Patrick J. Roberts,Kristan Rollins,Angela D. M. Kashuba,Mary F. Paine,Andrew C. Nelsen,Eric E. Williams,Cassandra Moran,Jatinder K. Lamba,Erin G. Schuetz,Roy L. Hawke	25
10	The Influence of CYP3A5 Expression on the Extent of Hepatic CYP3A Inhibition Is Substrate-Dependent: An in Vitro-in Vivo Evaluation 2007 ·Drug Metabolism and Disposition ·Nina Isoherranen,(unknown),Raymond C. Givens,Jatinder K. Lamba,Susan N. Pusek,E. Claire Dees,David K. Blough,Kazunori Iwanaga,Roy L. Hawke,Erin G. Schuetz,Paul B. Watkins,Kenneth E. Thummel,Mary F. Paine	34
11	Warfarin Dosing and the Promise of Pharmacogenomics 2007 ·Current Clinical Pharmacology ·(unknown),Roy L. Hawke,Craig R. Lee	16
12	Pharmacokinetics and Metabolic Profile of Free, Conjugated, and Total Silymarin Flavonolignans in Human Plasma after Oral Administration of Milk Thistle Extract 2007 ·Drug Metabolism and Disposition ·Zhiming Wen,(unknown),Sarah J. Schrieber,Roy L. Hawke,Michael Fried,Philip Coleridge Smith	153
13	Antimycotic Drug Discovery in the Age of Genomics 2005 ·PubMed ·John D. Cleary,Larry Walker,Roy L. Hawke	2
14	KUPFFER CELL-MEDIATED IL-2 SUPPRESSION OF CYP3A ACTIVITY IN HUMAN HEPATOCYTES 2004 ·Drug Metabolism and Disposition ·(unknown),Roy L. Hawke,Edward L. LeCluyse,Angela D. M. Kashuba	92
15	Gemcitabine pharmacokinetics and interaction with paclitaxel in patients with advanced non-small-cell lung cancer 2003 ·Cancer Chemotherapy and Pharmacology ·Stacy S. Shord,Stephanie Faucette,Heidi H. Gillenwater,S Pescatore,Roy L. Hawke,Mark A. Socinski,Celeste Lindley	31
16	The Effect of Cyclophosphamide with and without Dexamethasone on Cytochrome P450 3A4 and 2B6 in Human Hepatocytes 2002 ·Drug Metabolism and Disposition ·Celeste Lindley,Geraldine A. Hamilton,Jeannine S. McCune,Stephanie Faucette,Stacy S. Shord,Roy L. Hawke,Hongbing Wang,Darryl Gilbert,Summer Jolley,Bingfang Yan,Edward L. LeCluyse	81
17	Validation of Bupropion Hydroxylation as a Selective Marker of Human Cytochrome P450 2B6 Catalytic Activity 2000 ·Drug Metabolism and Disposition ·Stephanie Faucette,Roy L. Hawke,Edward L. LeCluyse,Stacy S. Shord,Bingfang Yan,Ronald M. Laethem,Celeste Lindley	302
18	Induction of cytochrome P450 3A4 activity by cyclophosphamide, alone and in combination with dexamethasone 1999 ·Clinical Pharmacology & Therapeutics ·Celeste Lindley,Jeannine S. McCune,Roy L. Hawke,(unknown),William P. Petros,Edward L. LeCluyse	1
19	Separation of Hydroxylated Metabolites of Fatty Acids (C₁₀-C₁₈) on a μPorasil Silica Column Using an Isocratic HPLC System 1986 ·Journal of Liquid Chromatography ·(unknown),Roy L. Hawke,Richard M. Welch	3
20	Major differences in the specificity and regulation of mouse renal cytochrome P-450-dependent monooxygenases. A comparison of xenobiotic and endogenous substrates. 1985 ·Molecular Pharmacology ·Roy L. Hawke,Richard M. Welch	7

About Roy L. Hawke

Roy L. Hawke is a scholar working on Pharmacology, Biochemistry and Hepatology, having authored 33 papers that have together received 1.4k indexed citations. Recurring topics across this work include Drug-Induced Hepatotoxicity and Protection (13 papers), Pharmacogenetics and Drug Metabolism (11 papers) and Silymarin and Mushroom Poisoning (9 papers). The work is most often cited by research in Pharmacology (791 citations), Hepatology (162 citations) and Pharmacology (237 citations). Roy L. Hawke has collaborated with scholars based in United States, Netherlands and United Kingdom. Frequent co-authors include Edward L. LeCluyse, Celeste Lindley, Stephanie Faucette, Stacy S. Shord, Michael Fried, Zhiming Wen, Bingfang Yan, Sarah J. Schrieber, Ronald M. Laethem and Angela D. M. Kashuba. Their work appears in journals such as Journal of Clinical Oncology, Hepatology and Journal of Lipid Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact